Skip to main content
. 2022 Nov 8;13:6740. doi: 10.1038/s41467-022-34495-z

Fig. 5. Depletion of NK cells reverses the antitumor effects of CD39i in vivo.

Fig. 5

A–C CD39i significantly inhibited the tumor growth and improved the overall survival rate in normal mice, but the effect of CD39i was remarkably reversed in the NK cell-depleted mice (n = 10 for each group). Comparisons of tumor growth curves were performed by a two-way ANOVA test followed by Tukey’s multiple comparison test. The log-rank (Mantel–Cox) test was used to compare the survival curves. D CD39i treatment increased the proportion of tumor infiltrated cDC1 (CD45 + CD11c + MHC II + CD103 + CD11b-) in control mice, but not in NK cells absent mice. The flow cytometry analyses were repeated 3 times with 5 samples in each group. E–G CD39i was confirmed to inhibit the progression of BC and improve the prognosis of mice, but it failed to effectively inhibit the growth of subcutaneous tumors or improve the mouse prognosis in cDC1-deficient Batf3−/− mice, n = 10 for each group. Comparisons of tumor growth curves were performed by a two-way ANOVA test followed by Tukey’s multiple comparison test. The log-rank (Mantel–Cox) test was used to compare the survival curves. Source data are provided as a Source Data file (A, C, E, G). Bar graphs show the mean ± SEM, and P-values <0.05 were considered significant: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.